Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03840928
Other study ID # GlobalHealthyLivingF
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2015
Est. completion date March 1, 2025

Study information

Verified date December 2023
Source Global Healthy Living Foundation
Contact Shilpa Venkatachalam, PhD
Phone (845) 348 0400
Email bnowell@ghlf.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with rheumatoid arthritis (RA), spondyloarthritis (SpA), other musculoskeletal conditions, chronic neurological conditions like migraine, chronic pulmonary conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, autoimmune dermatological conditions such as psoriasis, and other chronic inflammatory or immune-mediated conditions. In addition, since patients with chronic conditions often have other co-morbidities like cardiovascular health and obesity-related metabolic disorders, these conditions will also be included. Participants will provide information from their smartphones or personal computers. The information will be used by researchers and clinicians to help patients and their providers make better, more informed decisions about treatment of chronic conditions.


Description:

Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with rheumatoid arthritis (RA), spondyloarthritis (SpA), other musculoskeletal conditions, chronic neurological conditions like migraine, chronic pulmonary conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, autoimmune dermatological conditions such as psoriasis, and other chronic inflammatory or immune-mediated conditions. In addition, since patients with chronic conditions often have other co-morbidities like cardiovascular health and obesity-related metabolic disorders, these conditions will also be included. Participants will provide information from their smartphones or personal computers. The information will be used by researchers and clinicians to help patients and their providers make better, more informed decisions about treatment of chronic conditions. We have established a governance structure with highly engaged patients and stakeholders who will serve on a Patient Governor Group (PGG) and Research Advisory Board (RAB) to ensure Patient Power participant privacy and transparency about research activities. Online tools and a mobile application at me securely capture patient data. The software tools built include real-time connection to the adaptive version of NIH Patient Reported Outcomes Measurement Information System (PROMIS) instruments capturing patient reported data that minimizes participant burden and allows participants to immediately view their scores if they choose. The Patient Power App runs on both web browsers and smartphones with data stored in the Amazon Web Services (AWS) cloud, not on a participant's smartphone or browser. The App has four key design pillars: (1) Patient engagement, community integration and education by incorporating GHLF bloggers and chronic disease news and social media engagement to the app for education, support and research findings to be shared directly and immediately with those living with registry-eligible chronic conditions; (2) Personal longitudinal health and medication tracking by providing participants' access to their actively contributed patient reported outcome (PRO) and other health-related data (e.g. current and past medications). We will use messaging to encourage participants to regularly update their information, including medication information. For example, we may remind participants to contribute their medication information with the following message: "You don't have any active medications. You can record your medications in Patient Power. By adding your active medications, you will be able to see how your symptoms have changed since starting a new medication. Click here to start entering medications". (3) Health care decision making by allowing App users to share health tracking reports at their discretion with their providers or caregivers; and (4) Research opportunities by providing a platform where an array of new research opportunities can be browsed by participants to combat chronic diseases. The combination of solid governance structure with well-developed policies and procedures, engaged patient community, collaborative relationships with many research partners and our innovatively convenient and mobile approach to data collection make Patient Power a unique and powerful patient-led initiative in chronic disease research.


Recruitment information / eligibility

Status Recruiting
Enrollment 40000
Est. completion date March 1, 2025
Est. primary completion date March 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Self-report that a physician has given a diagnosis of a chronic condition listed in the registry. - The Registry is only intended at this time for residents of the United States and United States territories and Canada who are nineteen (19) years or older (for Puerto Rico residents, you must be 21 years or older to participate). Exclusion Criteria • Under 19 years old

Study Design


Related Conditions & MeSH terms

  • Alopecia
  • Alzheimer Disease
  • Amyotrophic Lateral Sclerosis
  • Angina, Unstable
  • Ankylosing Spondylitis
  • Arrythmia
  • Arteritis
  • Arthritis
  • Arthritis, Juvenile
  • Arthritis, Psoriatic
  • Asthma
  • Ataxia
  • Axial Spondyloarthritis
  • Bell Palsy
  • Brain Tumor
  • Cerebral Aneurysm
  • Chronic Inflammation
  • Chronic Liver Disease
  • Chronic Obstructive Pulmonary Disease
  • Cluster Headache
  • Congenital Heart Disease
  • Connective Tissue Diseases
  • Craniocerebral Trauma
  • Crohn Disease
  • Cystic Fibrosis
  • Dermatomyositis
  • Diabetes
  • Eczema
  • Epilepsy
  • Fibromyalgia
  • Giant Cell Arteritis
  • Gout
  • Guillain-Barre Syndrome
  • Head Injury
  • Headache
  • Heart Attack
  • Heart Defects, Congenital
  • Heart Diseases
  • Heart Failure
  • Heart Valve Diseases
  • High Blood Pressure
  • Hydrocephalus
  • Hyperostosis, Diffuse Idiopathic Skeletal
  • Hypertension
  • Inflammation
  • Inflammatory Bowel Diseases
  • Intracranial Aneurysm
  • Juvenile Idiopathic Arthritis
  • Liver Diseases
  • Lumbar Disc Disease
  • Lung Cancer
  • Lung Diseases, Obstructive
  • Lupus Erythematosus
  • Meningitis
  • Motor Neuron Disease
  • Multiple Sclerosis
  • Muscular Dystrophies
  • Muscular Dystrophy
  • Myocardial Infarction
  • Myositis
  • Obesity
  • Osteoarthritis
  • Osteoporosis
  • Parkinson Disease
  • Peripheral Arterial Disease
  • Peripheral Vascular Diseases
  • Polymyalgia Rheumatica
  • Polymyositis
  • Psoriasis
  • Psoriatic Arthritis
  • Pulmonary Disease, Chronic Obstructive
  • Relapsing Polychondritis
  • Rheumatoid Arthritis
  • Scleroderma
  • Sclerosis
  • Sleep Apnea
  • Spinal Cord Injuries
  • Spondylitis
  • Spondylitis, Ankylosing
  • Stroke
  • Syndrome
  • Temporal Arteritis
  • Tension-Type Headache
  • Undifferentiated Connective Tissue Disease
  • Undifferentiated Connective Tissue Diseases
  • Unstable Angina
  • Valve Heart Disease
  • Wounds and Injuries

Locations

Country Name City State
United States Global Healthy Living Foundation Upper Nyack New York

Sponsors (2)

Lead Sponsor Collaborator
Global Healthy Living Foundation University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Interference (PROMIS) 7 days
Primary Fatigue (PROMIS) 7 days
Primary Sleep Disturbance (PROMIS) 7 days
Primary Physical Function (PROMIS) 7 days
Primary RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health) 7 days
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2